AML

>

Latest News

New Combination Shows Strong Responses in Phase 2a Portion of AML Trial
New Combination Shows Strong Responses in Phase 2a Portion of AML Trial

March 27th 2024

A phase 1/2 trial showed that SLS009 in combination with azacitidine and venetoclax achieved a 50% response rate in relapsed/refractory acute myeloid leukemia.

LYT-200 Gains FDA Orphan Drug Designation in Acute Myeloid Leukemia
LYT-200 Gains FDA Orphan Drug Designation in Acute Myeloid Leukemia

March 13th 2024

FDA Lifts Clinical Hold on CAR T Study in AML
FDA Lifts Clinical Hold on CAR T Study in AML

February 12th 2024

FDA Halts Clinical Studies of Magrolimab in AML, MDS
FDA Halts Clinical Studies of Magrolimab in AML, MDS

February 7th 2024

Beat AML Study Highlights Influential Factors in AML Treatment
Beat AML Study Highlights Influential Factors in AML Treatment

February 6th 2024

Video Series
Video Interviews

More News